Proceedings (Aug 2019)
Synthesis, In Vitro Profiling, and In Vivo Efficacy Studies of a New Family of Multitarget Anti-Alzheimer Compounds
- Francisco Javier Pérez-Areales,
- María Garrido,
- Ester Aso,
- Manuela Bartolini,
- Angela De Simone,
- Alba Espargaró,
- Tiziana Ginex,
- Raimon Sabate,
- Belén Pérez,
- Vincenza Andrisano,
- Francisco Javier Luque,
- Isidro Ferrer,
- Francisco Ciruela,
- Angel Messeguer,
- Diego Muñoz-Torrero
Affiliations
- Francisco Javier Pérez-Areales
- Laboratory of Pharmaceutical Chemistry (CSIC Associated Unit), Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain
- María Garrido
- Department of Biological Chemistry and Molecular Modeling, Instituto de Química Avanzada de Catalunya (IQAC-CSIC), C/Jordi Girona, 18-26, E-08034 Barcelona, Spain
- Ester Aso
- Pathological Anatomy Unit, Pathology and Experimental Therapeutics Department, IDIBELL, and Neurosciencies Institute, University of Barcelona, and Biomedical Network Research Center on Neurodegenerative Diseases (CIBERNED), E-08907 L’Hospitalet de Llobregat, Spain
- Manuela Bartolini
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna, Via Belmeloro 6, I-40126 Bologna, Italy
- Angela De Simone
- Department for Life Quality Studies, University of Bologna, Corso d’Augusto 237, I-47921 Rimini, Italy
- Alba Espargaró
- Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain
- Tiziana Ginex
- Department of Nutrition, Food Sciences and Gastronomy, Faculty of Pharmacy and Food Sciences (Campus Torribera), and IBUB, University of Barcelona, Prat de la Riba 171, E-08921 Santa Coloma de Gramenet, Spain
- Raimon Sabate
- Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain
- Belén Pérez
- Department of Pharmacology, Therapeutics and Toxicology, Autonomous University of Barcelona, E-08193 Bellaterra, Spain
- Vincenza Andrisano
- Department for Life Quality Studies, University of Bologna, Corso d’Augusto 237, I-47921 Rimini, Italy
- Francisco Javier Luque
- Department of Nutrition, Food Sciences and Gastronomy, Faculty of Pharmacy and Food Sciences (Campus Torribera), and IBUB, University of Barcelona, Prat de la Riba 171, E-08921 Santa Coloma de Gramenet, Spain
- Isidro Ferrer
- Pathological Anatomy Unit, Pathology and Experimental Therapeutics Department, IDIBELL, and Neurosciencies Institute, University of Barcelona, and Biomedical Network Research Center on Neurodegenerative Diseases (CIBERNED), E-08907 L’Hospitalet de Llobregat, Spain
- Francisco Ciruela
- Pharmacology Unit, Pathology and Experimental Therapeutics Department, IDIBELL, and Neurosciencies Institute, University of Barcelona, E-08907 L’Hospitalet de Llobregat, Spain
- Angel Messeguer
- Department of Biological Chemistry and Molecular Modeling, Instituto de Química Avanzada de Catalunya (IQAC-CSIC), C/Jordi Girona, 18-26, E-08034 Barcelona, Spain
- Diego Muñoz-Torrero
- Laboratory of Pharmaceutical Chemistry (CSIC Associated Unit), Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain
- DOI
- https://doi.org/10.3390/proceedings2019022071
- Journal volume & issue
-
Vol. 22,
no. 1
p. 71
Abstract
Simultaneous modulation of several targets or pathological events with a key pathogenic role isa promising strategy to tackle thus far difficult-to-cure or incurable multifactorial diseases [...]
Keywords
- multitarget compounds
- multitarget-directed ligands
- acetylcholinesterase inhibitors
- butyrylcholinesterase inhibitors
- BACE-1 inhibitors, anti-aggregating agents
- antioxidant properties
- brain permeability
- in vivo efficacy studies.
